Efficacy of acitretin for porokeratosis in a child with chronic cutaneous graft versus host disease.

Abstract

Porokeratosis is a rare disorder of epidermal keratinization that is regarded as a precancerous. Recipients of hematopoietic stem cell transplantation (HSCT) have a greater risk of skin cancer; chronic graft versus host disease (GVHD) is an additional risk factor. A 16-year-old boy who had received HSCT for acute myelogenous leukemia was referred to us for sclerodermoid chronic cutaneous GVHD. Two years later, he developed disseminated porokeratosis with a few atypical lesions. Despite cryotherapy, numerous lesions of porokeratosis recurred rapidly. Acitretin resulted in good clinical response and reduced the rate of onset of new lesions.

• Authors: Riccardo G Borroni, Dimitri Poddighe, Marco Zecca, Valeria Brazzelli
• Journal: Pediatric dermatology (Pediatr Dermatol) 2013 Jan-Feb Vol. 30 Issue 1 Pg. 148-50 ISSN: 1525-1470 [Electronic] United States
• PMID: 22085032 (Publication Type: Case Reports, Journal Article)
• Copyright: © 2011 Wiley Periodicals, Inc.

Chemical References

• Acitretin

Topics

• Acitretin (therapeutic use)
• Adolescent
• Biopsy, Needle
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Follow-Up Studies
• Graft vs Host Disease (drug therapy, etiology)
• Hematopoietic Stem Cell Transplantation (adverse effects, methods)
• Humans
• Immunohistochemistry
• Leukemia, Myeloid, Acute (diagnosis, surgery)
• Male
• Porokeratosis (drug therapy, etiology, pathology)
• Risk Assessment
• Treatment Outcome